Although preclinical and initial clinical studies inhibiting EGFR and other RTKs, as well as PI3K and mTOR, have only shown modest efficacy in GBM so far [9,10], RTKs and downstream signaling components represent attractive targets for developing novel therapeutic strategies. This evidence concerns the gene MTOR and glioblastoma.